Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: A systematic review and meta-analysis

Clinical Cancer Research

Volumn 18, Issue 14, 2012, Pages 3972-3981

  Wu, Junjie ^a,c   Liu, Jie ^a   Zhou, Yuhao ^d   Ying, Jun ^e   Zou, Houdong ^d   Guo, Shicheng ^a   Wang, Lei ^c   Zhao, Naiqing ^b   Hu, Jianjun ^c   Lu, Daru ^a   Jin, Li ^a   Li, Qiang ^c   Wang, Jiu Cun ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; GLUTAMINE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TRYPTOPHAN; XRCC1 PROTEIN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; GENE; GENE FREQUENCY; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; OVERALL SURVIVAL; PHARMACOGENOMICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY CONTROL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; XRCC1 GENE;

ALLELES; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PLATINUM; POLYMORPHISM, GENETIC; PROGNOSIS; TREATMENT OUTCOME;

EID: 84863885563     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1531     Document Type: Review

References (45)

1. National Comprehensive Cancer Network, Inc. 2010 [homepage on the Internet]. Fort Washington, PA. Available from: http://www.nccn.org/.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. (Pubitemid 351521864)
3. Gazdar AF. DNA repair and survival in lung cancer-the two faces of Janus. N Engl J Med 2007;356:771-3. (Pubitemid 46294609)
4. Lindahl T, Wood RD. Quality control by DNA repair. Science 1999;286:1897-905. (Pubitemid 129515891)
5. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 2005;4:18.
6. Zhu G, Lippard SJ. Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand cross-links. Biochemistry 2009;48:4916-25.
7. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999;59:2557-61. (Pubitemid 29269097)
8. Yoon SM, Hong YC, Park HJ, Lee JE, Kim SY, Kim JH, et al. The polymorphism and haplotypes of XRCC1 and survival of non-smallcell lung cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:885-91.
9. Song D, Liu J, Wang Z, Song B, Li C. [Single nucleotide polymorphisms in XRCC1 and XPD and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer]. Chin J Gerontol 2007;27:1684-6.
10. Song D, Liu J, Wang Z, Song B, Li C. [Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer]. Cancer Res Prev Treat 2007;34:845-7.
11. Attia J, Thakkinstian A, D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol 2003;56:297-303. (Pubitemid 36593307)
12. Jiang DK, Ren WH, Yao L, Wang WZ, Peng B, Yu L. Meta-analysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk. Urology 2010;76:761-5.
13. Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, Duffy D, et al. Systematic review and meta-analysis of the association between β2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 2005;162:201-11. (Pubitemid 41373524)
14. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z. Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer 2008;112:1325-36. (Pubitemid 351429748)
15. Xiao P, Huang H, Zhou G, Lu Z. Gel immobilization of acrylamidemodified single-stranded DNA template for pyrosequencing. Electrophoresis 2007;28:1903-12. (Pubitemid 47040394)
16. Wan Y,Wang Y, Luo J, Lu Z. Bisulfite modification of immobilized DNAs for methylation detection. Biosens Bioelectron 2007;22:2415-21. (Pubitemid 46484227)
17. Xiao PF, Cheng L, Wan Y, Sun BL, Chen ZZ, Zhang SY, et al. An improved gel-based DNA microarray method for detecting single nucleotide mismatch. Electrophoresis 2006;27:3904-15. (Pubitemid 44608410)
18. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-91. (Pubitemid 35266288)
19. Zatloukal P, Petruzelka L,Zemanova M, Kolek V, Skrickova J, Pesek M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003;41:321-31. (Pubitemid 36970188)
20. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8. (Pubitemid 34438899)
21. Kelly K, Crowley J, Bunn PJ, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-8. (Pubitemid 32591438)
22. Johnson DH, Chang AY, Ettinger DS, Kim KM, Bonomi P. Recent advances with chemotherapy for NSCLC: the ECOG experience. Eastern Cooperative Oncology Group. Oncology (Williston Park) 1998;12:67-70.
23. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-601. (Pubitemid 41103746)
24. Zintzaras E, Lau J. Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol 2008;61:634-45. (Pubitemid 351766746)
25. Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol 2005;34:1319-28. (Pubitemid 41819539)
26. Yao CY, Huang XE, Li C, Shen HB, Shi MQ, Feng JF, et al. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev 2009;10:859-64.
27. de Las Peñas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006;17:668-75.
28. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009;10:118-23.
29. Yuan P, Liu L, Wu C, Zhong R, Yu D, Wu J, et al. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy. Cancer Biol Ther 2010;10:854-9.
30. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34. (Pubitemid 28562978)
31. Ades AE, Lu G, Higgins JP. The interpretation of random-effects metaanalysis in decision models. Med Decis Making 2005;25:646-54. (Pubitemid 41667133)
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
33. Deeks J, Higgins J, Altman D. Analyzing data and undertaking metaanalyses. In: Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions 5.0.1. Oxford, UK: The Cochrane Collaboration; 2008. p. 9.1-9.43.
34. Hong C, Xu Q, Yue Z, Zhang Y, Yuan Y. [Correlation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism]. Ai Zheng 2009;28:1291-7.
35. Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, et al. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 2009;65:230-6.
36. Gao C, Shi M, Wu J, Cao H, Feng J, Xu L. [Polymorphisms in XRCC1 gene and sensitivity to gemcitabine/cisplatin chemotherapy in non small cell lung cancer]. Pract J Cancer 2006;21:351-3.
37. Qian X, Qiu L, Yang Y, Jiang M, Zhang Y, Yu L, et al. [Predictive value of base-excision repair gene polymorphisms in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy]. J Modern Oncol 2010;18:1303-5.
38. Yuan P, Miao X, Zhang X, Wang Z, Tan W, Sun Y, et al. [XRCCl and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi 2006;28:196-9.
39. Wang Z, Miao X, Tan W, Zhang X, Xu B, Lin D. [Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer]. Chin J Cancer 2004;23:865-8.
40. Horgan AM, Yang B, Azad AK, Amir E, John T, Cescon DW, et al. Pharmacogenetic and germline prognostic markers of lung cancer. J Thorac Oncol 2011;6:296-304.
41. Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol 2004;49:119-33. (Pubitemid 38175439)
42. Funke S, Brenner H, Chang-Claude J. Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics 2008;9:1079-99.
43. Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, Yu LK, Song Y. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol 2011;28:315-21.
44. Rosell R, Lord RV, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002;38:217-27. (Pubitemid 35341796)
45. Wei Q, Frazier ML, Levin B. DNA repair: a double-edged sword. J Natl Cancer Inst 2000;92:440-1. (Pubitemid 30182874)